|
May 15
|
Q1 2024 Arcutis Biotherapeutics Inc Earnings Call
|
|
May 15
|
Arcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
|
|
May 14
|
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
|
|
May 13
|
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
|
|
Apr 29
|
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
|
|
Apr 26
|
Industry Analysts Just Made A Captivating Upgrade To Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts
|
|
Apr 24
|
Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?
|
|
Apr 10
|
Arcutis Appoints David Topper as Chief Financial Officer
|
|
Apr 8
|
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
|
|
Apr 1
|
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
|
|
Mar 28
|
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 19
|
Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
|
|
Mar 19
|
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
|
|
Mar 18
|
Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
|
|
Mar 11
|
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
|
|
Mar 10
|
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
|
|
Mar 9
|
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
|
|
Mar 9
|
Peabody Energy, Citi Trends, and More Stocks See Action From Activist Investors
|
|
Mar 4
|
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
|
|
Mar 4
|
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
|